WOLFGANG WINKELMAYER to Recombinant Proteins
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Recombinant Proteins.
Connection Strength
0.329
-
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
Score: 0.095
-
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.
Score: 0.093
-
Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014 May; 174(5):699-707.
Score: 0.088
-
Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009 Oct; 18(10):932-40.
Score: 0.016
-
Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients. Arch Intern Med. 2007 Apr 23; 167(8):840-6.
Score: 0.014
-
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia. 2005 May; 11(3):261-9.
Score: 0.012
-
Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004 Oct; 66(4):1712; author reply 1712-3.
Score: 0.011